Comparative effectiveness of first-line antiretroviral therapy
Author:
Publisher
Ovid Technologies (Wolters Kluwer Health)
Subject
Infectious Diseases,Immunology,Immunology and Allergy
Reference12 articles.
1. Antiretroviral drugs for treatment and prevention of HIV infection in adults: 2018 recommendations of the International Antiviral Society-USA Panel;Saag;JAMA,2018
2. Dolutegravir in antiretroviral-naive adults with HIV-1: 96-week results from a randomized dose-ranging study;Stellbrink;AIDS,2013
3. Brief report: dolutegravir plus abacavir/lamivudine for the treatment of HIV-1 infection in antiretroviral therapy-naive patients: week 96 and week 144 results from the SINGLE randomized clinical trial;Walmsley;J Acquir Immune Defic Syndr,2015
4. Once daily dolutegravir (S/GSK1349572) in combination therapy in antiretroviral-naive adults with HIV: planned interim 48 week results from SPRING-1, a dose-ranging, randomised, phase 2b trial;van Lunzen;Lancet Infect Dis,2012
5. Once-daily dolutegravir versus darunavir plus ritonavir for treatment-naive adults with HIV-1 infection (FLAMINGO): 96 week results from a randomised, open-label, phase 3b study;Molina;Lancet HIV,2015
Cited by 32 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Three Year Outcomes after Programmatic Transitioning to Dolutegravir in the Context of Severe Civil Unrest in Haiti;2024-08-14
2. Liver function tests, CD4+ counts, and viral load among people living with HIV on dolutegravir compared to efavirenz-based cART; a comparative cross-sectional study;Heliyon;2024-06
3. Time from treatment initiation to HIV viral suppression in public care facilities in Brazil: a nationwide linked databases cohort;2024-05-31
4. Cost-effectiveness of intervention combinations towards the elimination of vertical transmission of HIV in limited-resource settings: a mathematical modelling study;The Lancet Global Health;2024-03
5. Outcomes of severely ill patients with AIDS treated with efavirenz or dolutegravir: a multicenter, observational study;Frontiers in Medicine;2024-02-28
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3